Korea’s Powerhouse Ambitions Build On Innovation-Fostering Policies
Financing Late-Stage Trials 'Biggest Obstacle'
South Korea’s Second Vice Minister of Health and Welfare Minsoo Park talks to the Pink Sheet about a broad range of issues including the government’s priorities for innovative R&D, as well as challenges in reaching these goals, measures to deal with the deterioration in biopharma investment sentiment and regulatory changes to support drug development.
You may also be interested in...
At the recent World Bio Summit in Seoul, global health leaders discussed international cooperation strategies and policies to prepare for the next pandemic, with a focus on rapid vaccine development.
Recent sizable out-licensing deals with global big pharma firms are raising hopes of a recovery in Korean biopharma alliances and also point to possible changes in deal structures towards international norms.
Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.